2026년 1월 연구원 논문
배은진 연구교수 (신경과학연구소)
Anti-TLR2 immunotherapy modulates neuron-to-oligodendrocyte propagation of α-synuclein in mouse and human models
Nature Communications
Intracellular accumulation of α-synuclein (αSyn) aggregates is a hallmark of
synucleinopathies, such as Parkinson’s disease (PD) and multiple system
atrophy (MSA). In MSA, αSyn aggregates form glial cytoplasmic inclusions
(GCIs) in oligodendrocytes, despite their low expression of αSyn. Here, we
demonstrate that neuron-to-oligodendrocyte propagation of αSyn, via Tolllike
receptor 2 (TLR2) contributes to GCI formation. Male transgenic mice
expressing the A53T mutant human αSyn exclusively in neurons, and the
preformed fibril injection model exhibited MSA-like pathology, including GCI
formation, gliosis, and neuroinflammation in the white matter. Notably,
administration of NM-101, an anti-TLR2 antibody, significantly alleviated these
pathological features. Transcriptome analyses revealed demyelination-related
features in MSA oligodendrocytes and experimental models. Elevated TLR2
expression in MSA oligodendrocytes inversely correlated with MBP expression,
and the correlation was absent in PD. In the transgenic mouse model, NM101
administration rescued the demyelination phenotype. These findings
highlight anti-TLR2 immunotherapy as a potential disease-modifying
approach for MSA.

